Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer

BACKGROUND: Cisplatin is a first-line drug for the treatment of human non-small cell lung cancer (NSCLC); however, the majority of patients will develop drug resistance after treatment. In order to overcome cisplatin resistance, it is important to understand the mechanisms underlying the resistance....

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wenjing, Zhao, Mengyue, Cui, Lijuan, Ren, Yong, Zhang, Jingyuan, Chen, Junli, Jia, Lina, Zhang, Jiayu, Yang, Jingyu, Chen, Guoliang, Ashby, Charles R., Wu, Chunfu, Chen, Zhe-Sheng, Wang, Lihui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466461/
https://www.ncbi.nlm.nih.gov/pubmed/32878625
http://dx.doi.org/10.1186/s12943-020-01256-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466461/
https://www.ncbi.nlm.nih.gov/pubmed/32878625
http://dx.doi.org/10.1186/s12943-020-01256-9

Ejemplares similares